Data gathered: April 15
AI Stock Analysis - Tempest Therapeutics (TPST)
Analysis generated May 8, 2024. Powered by Chat GPT.
Tempest Therapeutics is a biotechnology company focused on discovering and developing small molecule therapeutics. The company's goal is to address unmet medical needs in the field of oncology by targeting the tumor microenvironment and enhancing the body's immune response to fight cancer. With a robust pipeline of potential therapies, Tempest Therapeutics operates in a high-stakes industry where innovation and speed to market are critical.
Stock Alerts - Tempest Therapeutics (TPST)
 |
Tempest Therapeutics | April 14 Price is up by 7.1% in the last 24h. |
|
Tempest Therapeutics | April 11 Price is up by 7.7% in the last 24h. |
|
Tempest Therapeutics | April 10 Price is down by -10.5% in the last 24h. |
|
Tempest Therapeutics | April 9 Price is down by -5.3% in the last 24h. |
Alternative Data for Tempest Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | 1 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 359 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,728 | Sign up | Sign up | Sign up |
| Twitter Followers | 382 | Sign up | Sign up | Sign up |
| Twitter Mentions | 79 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 30 | Sign up | Sign up | Sign up |
About Tempest Therapeutics
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.
| Price | $6.96 |
| Target Price | Sign up |
| Volume | 55,830 |
| Market Cap | $22M |
| Year Range | $5.86 - $20.15 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Tempest Therapeutics’ (TPST) “Neutral” Rating Reaffirmed at HC WainwrightApril 12 - ETF Daily News |
 |
Scotiabank Reiterates Sector Perform Rating for Tempest Therapeutics (NASDAQ:TPST)April 11 - ETF Daily News |
|
Research Analysts Issue Forecasts for TPST Q1 EarningsMarch 31 - ETF Daily News |
|
FY2028 Earnings Estimate for TPST Issued By William BlairMarch 30 - ETF Daily News |
|
Tempest Therapeutics (NASDAQ:TPST) Given New $7.00 Price Target at ScotiabankMarch 29 - ETF Daily News |
|
HC Wainwright Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $16.00March 29 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 490,000 | 240,000 | 240,000 | -14M | -14M | -0.310 |
| Q3 '24 | 0 | 0 | 0 | -11M | -10M | -0.410 |
| Q2 '24 | 0 | 160,000 | -160,000 | -9.6M | -9M | -0.420 |
| Q1 '24 | 0 | 88,000 | -88,000 | -7.9M | -7.4M | -0.360 |
| Q4 '23 | 0 | 85,000 | -85,000 | -7.5M | -7M | -0.380 |
Insider Transactions View All
| Versant Ventures IV, LLC filed to sell 209,941 shares at $1.1. August 12 '24 |
| Versant Ventures IV, LLC filed to sell 597,940 shares at $1.4. August 12 '24 |
| Brady Stephen R filed to buy 46,376 shares at $2.1. July 8 '24 |
| Whiting Samuel filed to buy 9,573 shares at $2.1. July 3 '24 |
| Trojanowski Justin filed to buy 22,168 shares at $2.2. July 2 '24 |
Similar companies
Read more about Tempest Therapeutics (TPST) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Tempest Therapeutics?
The Market Cap of Tempest Therapeutics is $22M.
What is the current stock price of Tempest Therapeutics?
Currently, the price of one share of Tempest Therapeutics stock is $6.96.
How can I analyze the TPST stock price chart for investment decisions?
The TPST stock price chart above provides a comprehensive visual representation of Tempest Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tempest Therapeutics shares. Our platform offers an up-to-date TPST stock price chart, along with technical data analysis and alternative data insights.
Does TPST offer dividends to its shareholders?
As of our latest update, Tempest Therapeutics (TPST) does not offer dividends to its shareholders. Investors interested in Tempest Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tempest Therapeutics?
Some of the similar stocks of Tempest Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.